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The pikromycin polyketide synthase (PKS) is
unique in its ability to generate both 12 and 14
membered ring macrolactones. As such, dis-
section of the molecular basis for controlling
metabolic diversity in this system remains an
important objective for understanding modular
PKS function and expanding chemical diversity.
Here, we describe a series of experiments de-
signed to probe the importance of the protein-
protein interaction that occurs between the final
two monomodules, PikAIII (module 5) and Pi-
kAIV (module 6), for the production of the 12
membered ring macrolactone 10-deoxymethy-
nolide. The results obtained from these in vitro
studies demonstrate that PikAIII and PikAIV
generate the 12 membered ring macrocycle
most efficiently when engaged in their native
protein-protein interaction. Accordingly, the
data are consistent with PikAIV adopting an al-
ternative conformation that enables the termi-
nal thioesterase domain to directly off-load
the PikAIII-bound hexaketide intermediate for
macrocyclization.
INTRODUCTION
Polyketides are a diverse class of natural products that are
known to possess a wealth of medicinally important bio-
logical activities. The biosynthesis of macrolide polyketide
compounds occurs via a stepwise mechanism that is cat-
alyzed by type I modular polyketide synthases (PKSs).
These modular PKSs are comprised of a number of large,
multifunctional enzymes that are responsible for catalyz-
ing the initiation, elongation, and reductive steps that ulti-
mately give rise to the characteristic macrolactone scaf-
fold. For type I PKSs, the extension of a polyketide chain
by two carbon atoms requires a minimum of three protein
domains, the ketosynthase (KS), acyl transferase (AT), and
acyl carrier protein (ACP) that collectively comprise a PKS944 Chemistry & Biology 14, 944–954, August 2007 ª2007 Elsmodule. Within the elongation module, the AT domain is
responsible for recognizing and loading the appropriate
acyl-CoA extender unit onto the ACP domain. Subse-
quently, the KS domain catalyzes a decarboxylative con-
densation reaction between the ACP-bound extender
unit and the growing polyketide chain, resulting in an
ACP-bound elongated polyketide intermediate. In addi-
tion to these three core domains, each elongation module
may contain up to three additional domains that are re-
sponsible for the reductive processing of the b-keto
functionality prior to the subsequent extension step. The
presence of a ketoreductase (KR) domain gives rise to
a b-hydroxyl group, the presence of both a KR and a dehy-
dratase (DH) domain generates an alkene, while the com-
bination of KR, DH, and enoyl reductase (ER) results in
complete reduction to the alkane. Finally, termination of
polyketide biosynthesis is typically catalyzed by a thioes-
terase (TE) domain located at the carboxy terminus of the
final elongation module.
The pioneering sequence analysis of the biosynthetic
gene cluster for the 6-deoxyerythronolide B (DEBS) PKS
revealed that both the length and degree of b-keto re-
duction of the polyketide chain are determined by the se-
quential arrangement of extension and reductive domains
within the PKS system [1, 2]. This colinear relationship has
been exploited to rationally engineer polyketide products
via molecular genetic manipulation of PKS systems [3, 4].
However, analysis of several recently identified modular
PKS systems has challenged the ‘‘one extension permod-
ule’’ paradigm. For example, iterative polyketide extension
by a single PKSmodule has been implicated in the biosyn-
thesis of several natural products, suggesting that alterna-
tive activities ofmodules can lead to structures that cannot
be predicted from sequence analysis alone [5–9].
Pikromycin is a naturally occurring ketolide antibiotic
that is produced by a type I PKS inStreptomyces venezue-
lae ATCC 15439. Unlike other reported type I PKS sys-
tems, the pikromycin PKS demonstrates the unique ability
to efficiently generate two macrolactone products of dif-
fering ring size. Premature termination of polyketide bio-
synthesis at the penultimate elongation module, PikAIII,
results in generation of the 12 membered ring macro-
lactone, 10-deoxymethynolide (10-dml), while continued
elongation through the final elongation module, PikAIV,evier Ltd All rights reserved
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10-Deoxymethynolide Synthesis by the Pik PKSFigure 1. The Pikromycin Polyketide
Synthase
The pikromycin PKS is comprised of a single
loading module (LM) and six elongation mod-
ules that span four polypeptide chains (PikAI-
PikAIV). Interpolypeptide interactions are facil-
itated by docking domains that reside at the
termini of the individual polypeptides. Chain
elongation through PikAIII followed by thio-
esterase catalyzed termination results in the
12 membered macrolactone product, 10-de-
oxymethynolide, while continued elongation
of the polyketide chain produces the 14 mem-
bered macrolactone, narbonolide. Both prod-
ucts undergo further processing via a glycosyl
transferase and P450 hydroxylase to yield the
methymycin and pikromycin suite of anti-
biotics. Abbreviations: KS, ketosynthase; AT,
acyl transferase; ACP, acyl carrier protein;
TE, thioesterase.yields a heptaketide intermediate that is cyclized to the 14
membered ring macrolactone, narbonolide (Figure 1).
Each of thesemacrolactone products is further elaborated
via downstream glycosylation and hydroxylation reactions
to yield a series of antibiotics that includes the 12 mem-
bered ring macrolides methymycin, neomethymycin, and
novamethymycin, as well as the 14 membered ring mac-
rolides pikromycin, neopikromycin, and novapikromycin
[10–12].
Insight into the mechanism that directs the pikromycin
PKS to produce two distinct macrolactones could facili-
tate the development of a powerful metabolic engineering
tool for assembly of novel biologically active compounds.
Despite much effort, the precise catalytic events that give
rise to the two different macrolactone products from this
system remain unclear. It has previously been established
that inactivation of the TE domain of PikAIV eliminates the
production of both 10-dml and narbonolide [13]; hence,
the PikAIII bound hexaketide intermediate must be pre-
sented to the terminal TE domain of PikAIV for 10-dml
biosynthesis. Given the monomodular arrangement of
PikAIII and PikAIV, several hypothetical paths are possi-
ble that guide the hexaketide chain to the TE domain. For
example, a direct interaction between the ACP5 domain
of PikAIII and the TE domain of PikAIV might facilitate
the interdomain transfer of the hexaketide precursor. Such
a transfer could be achieved within the context of the
native intermodular docking-domain-mediated protein-
protein interaction that naturally occurs between the ACP5
domain and the KS6 domain [14], assuming that the
PikAIVmonomodule is sufficiently flexible to enable the TE
to reach the ACP domain of PikAIII. Alternatively, the
monomodular arrangement of PikAIII and PikAIV might
enable a direct domain-domain interaction that is inde-
pendent of the ACP5 and KS6 docking domains. Finally,
if PikAIII and PikAIV can only interact through their re-
spective docking domains, the hexaketide chain couldChemistry & Biology 14, 94reach the TE domain by passing through PikAIV in the ab-
sence of a final elongation step (e.g., modular skipping)
[15, 16].
Our long-standing interest in developing a detailed un-
derstanding of the pikromycin PKS biosynthetic system
has motivated our continued dissection of the biochemi-
cal steps leading to formation of the 12 membered ring
macrolactone, 10-dml. Herein, we describe a series of
in vitro experiments that probe the importance of the inter-
modular docking domains between PikAIII and PikAIV for
the production of 10-dml. Taken together, the results of
this work demonstrate that PikAIII and PikAIV must en-
gage in their docking-domain-mediated protein-protein
interaction in order to facilitate efficient TE-catalyzed lac-
tonization of the PikAIII-bound hexaketide intermediate to
generate the 12 membered ring macrolactone product.
RESULTS
Mutation of PikAIV Catalytic Domains
In vitro investigations into multiple macrolactone produc-
tion by the pikromycin PKS were initiated by first examin-
ing whether catalytic competency of PikAIV was a neces-
sary requirement for 10-dml production. Specifically, we
sought to systematically probe the importance of each
of the four catalytic protein domains of PikAIV in 10-dml
biosynthesis. To this end, point mutations, serving to ef-
fectively inactivate each individual domain (DKS, C207A;
DAT, S652A; DACP, S980A; DTE, S1196A) were intro-
duced via PCR mutagenesis into the expression plasmid
encoding wild-type pikAIV. Each of the four mutant PikAIV
modules was coexpressed in E. coli with the B. subtilis
phosphopantetheinyltransferase in order to ensure effec-
tive posttranslational modification to the holo-ACP do-
main [17]. Following purification, apo to holo conversion
of the ACP domains was verified by FT-ICR MS analysis
(data not shown). Each of the mutants was assessed for4–954, August 2007 ª2007 Elsevier Ltd All rights reserved 945
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10-Deoxymethynolide Synthesis by the Pik PKSFigure 2. Activity of PikAIII + PikAIV Mu-
tants
(A) Radio-TLC of reaction products produced
by PikAIII + PikAIV mutants. Mutants of PikAIV
were each incubated with PikAIII in the
presence of the synthetic pentaketide NAC
thioester and 2-[14C]-methylmalonyl-CoA as
described in the experimental procedures.
The reaction products were resolved by TLC
(5% MeOH in CHCl3) and subsequently visual-
ized with a Typhoon phosphorimager.
(B) Michaelis-Menten plots of PikAIII + PikAIV
(DAT) and PikAIII + PikAIV(DACP). The aver-
ages of data points obtained from at least three
independent determinations are plotted. The
curves represent fits of the data calculated by
nonlinear regression. Error bars were gener-
ated from the standard deviation within each
point.its ability to produce both 10-dml and narbonolide when
combined with PikAIII and a pentaketide N-acetyl cyste-
amine (NAC) thioester substrate in vitro [18]. Significantly,
none of the four PikAIV mutants was capable of catalyzing
synthesis of the 14 membered ring macrolactone narbo-
nolide (Figure 2A). However, each mutant, with the excep-
tion of PikAIV(DTE), supported production of the smaller
macrolactone product 10-dml, suggesting that these do-
main-level activities are not required for synthesis of the
smaller macrocycle (Figure 2A).
The efficiency of 10-dml synthesis by PikAIV(DAT) and
PikAIV(DACP), in the presence of PikAIII, was further in-
vestigated through detailed steady-state kinetic analysis
(Figure 2B). For comparison, a parallel analysis was per-
formed with wild-type PikAIII and PikAIV (see the Supple-
mental Data available with this article online and Table 1).
Kinetic parameters determined for this control pairing
are in close agreement with previous reports (kcat = 3.0 ±
0.03 min1, KM = 0.31 ± 0.03 mM) [18]. Specifically, both
PikAIV(DAT) and PikAIV(DACP) display similar apparent
kcat values for 10-dml production, which are approxi-
mately 2-fold lower than the calculated kcat from wild-
type PikAIII and PikAIV (Table 1). Likewise, both PikAIV
mutants display similar apparent KM values that are also
reduced 2-fold when compared to the KM from PikAIII
and PikAIV. The equivalent decrease in the apparent ki-946 Chemistry & Biology 14, 944–954, August 2007 ª2007 Elsnetic parameters for both mutants results in a specificity
constant (kcat/KM) that is comparable to wild-type (Table
1), further emphasizing the noncritical role of these cata-
lytic domains in 10-dml production.
PikAIII and PikAIV Docking-Domain Truncations
Following analysis of PikAIV catalytic domains in macro-
cyclic ring formation, we next investigated the role of the
intermodular docking domains between PikAIII and PikAIV
in 10-dml production. The putative docking domains of
PikAIII and PikAIV were predicted from multiple sequence
alignment and secondary structural prediction, as well as
the NMR solution structure of the docking-domain inter-
action that occurs between DEBS2 and DEBS3 [19].
Guided by this information, partial deletions of both PikAIII
C-terminal and PikAIV N-terminal docking domains (here-
after referred to as PikAIII[DDock] and PikAIV[DDock])
were generated (Figures 3A and 3B).
PikAIII(DDock) and PikAIV(DDock) were each coex-
pressed in E. coli with the phosphopantetheinyl transfer-
ase from B. subtilis in order to facilitate efficient phospho-
pantetheinylation of the ACP domains [17]. Following
purification, the extent of apo to holo conversion of the
ACP domains in both truncated monomodules was as-
sessed by FT-ICR-MS analysis and determined to be
comparable to wild-type (>90%, Supplemental Data).evier Ltd All rights reserved
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10-Deoxymethynolide Synthesis by the Pik PKSFigure 3. PikAIII(DDock) and PikAIV
(DDock): Design and Activity
(A) Multiple sequence alignment of the helical
N-terminal docking domains from the pikromy-
cin and DEBS PKS. PikAIV(DDock) is the result
of truncating the first 14 amino acids (in italics)
of PikAIV.
(B) Multiple sequence alignment of partial C-
terminal docking domains from the pikromycin
and DEBS PKS. PikAIII(DDock) is the result of
truncating the final 19 amino acids (in italics)
of PikAIII that comprise helix 3.
(C) Radio-TLC of reaction products produced
by the truncated pikromcyin modules. PikAIII
(DDock) or PikAIV(DDock) was paired with their
respective partner wild-type or truncatedmod-
ule in the presence of the synthetic pentaketide
NAC thioester and 2-[14C]-methylmalonyl-CoA
as described in the experimental procedures.
Likewise, PikAIII or PikAIII(DDock) was paired
with recombinant pikromycin TE under iden-
tical experimental conditions. The reaction
products were resolved by TLC (5% MeOH in
CHCl3) and subsequently visualized by using
a Typhoon phosphorimager.We assessed the ability of both PikAIII(DDock) and
PikAIV(DDock) to produce 10-dml and narbonolide from
the synthetic pentaketide NAC thioester substrate when
paired with their respective complementary wild-type
module. As shown in Figure 3C, exclusive formation of
10-dml, with no detectable 14 membered ring product,
was observed in assays that utilized either truncated
monomodule. These data reveal that the native protein-
protein interaction that typically occurs between PikAIII
and PikAIV has been disrupted.
In vitro, both PikAIII(DDock) and PikAIV(DDock) demon-
strate the ability to catalyze the formation of the smaller
macrolactone product (Figure 3C, lanes 2 and 3); how-
ever, the extended time course required to observe prod-
uct accumulation (i.e., 75min versus 15min) suggests that
the efficiency of the synthesis of the 12 membered ring
macrocycle by the truncated monomodules is compro-
mised significantly relative to wild-type. Steady-state ki-
netic parameters were determined for the synthesis of
10-dml by both PikAIII(DDock) and PikAIV(DDock) whenChemistry & Biology 14, 944paired with their wild-type partner monomodule (Figures
4A and 4B). As summarized in Table 1, both PikAIII(DDock)
and PikAIV(DDock) display apparent kcat values
(0.044 min1 and 0.053 min1), which are significantly de-
creased relative to the kcat observed with wild-type PikAIII
and PikAIV. The apparent KM values for PikAIII(DDock)
and PikAIV(DDock) decreased 3- to 5-fold compared to
wild-type, resulting in specificity constants (kcat/KM) that
were 14- and 8-fold lower, respectively. Combining PikAIII
(DDock) and PikAIV(DDock) together did not result in an
additional rate decrease; the kinetic parameters were
comparable to those obtained when either truncated
monomodule was paired with its wild-type partner (Fig-
ure 4C and Table 1).
Thioesterase-Mediated 10-Deoxymethynolide
Production
Theobservation that 10-dml couldbeproduced, albeit inef-
ficiently, in a reaction mixture containing either truncated
monomodule prompted us to explore the possible–954, August 2007 ª2007 Elsevier Ltd All rights reserved 947
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10-Deoxymethynolide Synthesis by the Pik PKSTable 1. Steady-State Kinetic Parameters for 10-Deoxymethynolide Production by PikAIV Mutants, PikAIII(DDock),
and PikAIV(DDock)
Modules kcat (min
1) KM (mM) kcat/KM (min
1 $ mM1) Relative kcat
Relative
kcat/KM
PikAIII + PikAIVa,b 2.0 ± 0.02 0.31 ± 0.08 6.5 ± 1.7 1 1
PikAIII + PikAIV(DAT) 0.91 ± 0.09 0.17 ± 0.05 5.4 ± 1.7 0.46 0.83
PikAIII + PikAIV(DACP) 0.92 ± 0.05 0.15 ± 0.03 6.1 ± 1.3 0.46 0.94
PikAIII(DDock) + PikAIV 0.044 ± 0.003 0.095 ± 0.02 0.46 ± 0.10 0.02 0.07
PikAIII + PikAIV(DDock) 0.053 ± 0.002 0.064 ± 0.01 0.83 ± 0.13 0.03 0.13
PikAIII(DDock) +
PikAIV(DDock)
0.051 ± 0.004 0.093 ± 0.03 0.55 ± 0.18 0.03 0.08
PikAIII +
Pik Thioesterase
0.12 ± 0.01 0.22 ± 0.06 0.55 ± 0.21 0.06 0.08
PikAIII(DDock) +
Pik Thioesterase
0.16 ± 0.002 0.08 ± 0.003 2.0 ± 0.8 0.08 0.3
All reported errors represent the standard error of the mean.
a Independently determined for this report (see the Supplemental Data).
b Previously reported values: kcat = 3.0 min
1 and KM = 0.25 mM [18].occurrence of a direct interaction between the penultimate
elongation module, PikAIII, and the terminal TE domain of
PikAIV. Specifically, we examined the ability of the excised
recombinant pikromycin TE domain [20, 21] to catalyze
macrolactonization of the PikAIII bound hexaketide inter-
mediate into 10-dml.When assayed in combinationwith ei-
ther PikAIII or PikAIII(DDock), pikromycin TE catalyzed for-
mation of 10-dml (Figure 3C, lanes 4 and 5). As with the
truncated monomodules, steady-state kinetic analysis
confirmed the poor efficiency of product formation (Figures
4D and4E andTable 1) relative towild-type PikAIV. The ap-
parent kcat for the combination of PikAIII and was 0.12
min1, while the combination of PikAIII(DDock) and pikro-
mycin TE gave a kcat of 0.16 min
1. Although these values
are slightly greater than those observed in assays contain-
ing the truncated modules, they represent a rate that is ap-
proximately 50-fold slower than the wild-type PikAIII and
PikAIV interaction that leads to 10-dml production.
Titration of PikAIII Docking Domain:
Effect on Macrolactone Production
To probe further the significance of the PikAIII and PikAIV
interaction in macrolactone production by the pikromycin
PKS, competition experiments were performed with the
objective of disrupting the native intermodular protein-pro-
tein interaction. Previously, Tsuji et al. demonstrated that
the synthetic N-terminal docking domain of DEBS2 could
effectively compete with DEBS module 3 for interaction
with DEBSmodule 2 [22]. Based on this, it was anticipated
that disruption of the PikAIII and PikAIV interaction could
be achieved by supplementing reaction mixtures with in-
creasing concentrations of the discrete PikAIII C-terminal
docking domain. The C-terminal docking domain of PikAIII
(ACPdock) was successfully generated in E. coli as a dis-
crete, soluble protein. Following purification, ACPdock
was titrated into reaction mixtures containing PikAIII and948 Chemistry & Biology 14, 944–954, August 2007 ª2007 ElsePikAIV, and a profound impact on production of bothmac-
rolactone productswas observed (Figure 5A). The addition
of ACPdock in 10- to 50-fold excess relative to PikAIII and
PikAIV resulted in an approximate 2- to 4-fold reduction in
both narbonolide and 10-dml synthesis (Figure 5B). The
observed decrease in macrolactone synthesis was due
to specific competition between ACPdock and PikAIII for
PikAIV, as the addition of the C-terminal docking domain
from DEBS2 (DEBS2 ACPdock) did not affect levels of
macrolactone formation (Figure 5B).
DISCUSSION
The ability to produce recombinant PikAIII and PikAIV in
E. coli [23, 24], coupled with recent advances in the syn-
thesis of late stage pikromycin chain elongation intermedi-
ates [18, 20], presents the opportunity to perform detailed
in vitro characterization of reactions catalyzed by the final
two monomodules of pikromycin biosynthesis. It has re-
cently been demonstrated that the in vitro combination
of PikAIII and PikAIV can extend a synthetic pentaketide
N-acetyl cysteamine thioester substrate to generate both
10-dml and narbonolide [18]. Development of this in vitro
system has enabled detailed biochemical studies of the
molecular mechanisms involved in production of both
10-dml and narbonolide by the pikromycin PKS system.
Since elucidation of the pikromycin biosynthetic gene
cluster [25], events guiding the fate of the pikromycin hex-
aketide chain elongation intermediate have been the sub-
ject of much investigation. Initially, an in vivo N-terminally
truncated form of PikAIV was proposed to catalyze the
synthesis of 10-dml due to the inability of the KS domain
to catalyze normal condensation activity [13]; however,
the observation that full-length recombinant PikAIV can
support 10-dml synthesis in vitro does not fully support
this model [18]. More recently, a series of in vivovier Ltd All rights reserved
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10-Deoxymethynolide Synthesis by the Pik PKSFigure 4. Michaelis-Menten Plots of 10-Deoxymethynolide Formation by Mutant Pikromycin Modules
The averages of data points obtained from at least three independent determinations are plotted. Error bars were generated from the standard
deviation within each point. (A): PikAIII(DDock) + PikAIV; (B) PikAIII + PikAIV(DDock); (C) PikAIII(DDock) + PikAIV(DDock); (D) PikAIII + Pik TE;
(E) PikAIII(DDock) + Pik TE.experiments has suggested that all four domains of PikAIV
are required for 10-dml production by the pikromycin PKS
[15]. This observation led to the hypothesis that the hexa-
ketide intermediate must pass through PikAIV, without
undergoing extension, in order to reach the terminal TE
domain.
To investigate this proposed domain-skipping hypothe-
sis, each of the four domains that are encompassed within
PikAIV was inactivated via site-directed mutagenesis and
subsequently assessed for its ability to produce 10-dml
when paired with PikAIII in vitro. None of the PikAIV mu-
tants supported narbonolide production; however, with
the exception of PikAIV(DTE), 10-dml synthesis was ob-
served with all mutant PikAIV modules. These observa-
tions imply that the core catalytic domains that comprise
PikAIV are not required for generation of the 12membered
ring macrolactone product, a result that contradicts the
previously proposed in vivo PikAIV skipping model [15].
Furthermore, detailed kinetic analysis of 10-dml produc-
tion by PikAIV(DAT) and PikAIV(DACP) clearly demon-
strated that the production efficiency of the smaller mac-
rolactone product, relative to wild-type, is unaffected
when the AT and ACP domain are inactive. Such a result
would not be expected if these protein domains were, as
previously proposed, required for the synthesis of the 12
membered ring macrolactone.
Based on the in vitro activity of the PikAIV mutants, we
hypothesized that the generation of 10-dml by the pikro-
mycin PKS system results from the direct transfer and lac-
tonization of the PikAIII-bound hexaketide intermediate byChemistry & Biology 14, 9the terminal TE domain of PikAIV. If so, the monomodular
organization of PikAIII and PikAIV may permit the terminal
TE domain to nonspecifically interact with the ACP do-
main of PikAIII. Alternatively, the interaction of PikAIII
and PikAIV via their respective docking domains may be
required to enable the terminal TE domain to efficiently
access the ACP-bound hexaketide intermediate.
The interaction between modules leading to premature
lactonization has previously been investigated using the
erythromycin PKS system (6-deoxyerythronolide B syn-
thase, DEBS) [26]. In these studies, the combination of
DEBS1 and DEBS module 3 containing an engineered C-
terminal TE domain was observed to produce a triketide
lactone as well as the expected tetraketide lactone prod-
uct. Moreover, the rate of triketide lactone synthesis was
reportedly 10-fold higher when DEBS1 was paired with
the DEBS module 3-TE fusion protein compared with the
excised recombinant DEBS TE alone. This suggests that
despite the normal protein-protein interaction between
DEBS1andDEBSmodule3 that allows intermodular trans-
fer of the polyketide intermediate, the covalently linked TE
domain can compete for the triketide chain and produce
the triketide lactone. Extrapolation of this observation to
the pikromycin PKS systemwould suggest that the TE do-
mainof thePikAIVproteinmustcompete for thehexaketide
chain as it is being transferred to the KS6 active site.
It has previously been established that within PKS
systems, docking domains serve an essential role in inter-
polypeptide communication [14, 27, 28]. NMR studies of
docking-domain interactions from the DEBS PKS system44–954, August 2007 ª2007 Elsevier Ltd All rights reserved 949
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10-Deoxymethynolide Synthesis by the Pik PKSFigure 5. ACPdock Competition with PikAIII for Interaction with PikAIV
Reaction mixtures containing wild-type PikAIII and PikAIV were titrated with increasing amounts of the C-terminal docking domain of PikAIII (ACP-
dock) as described in the experimental procedures. The reaction products were resolved by TLC (5% MeOH in CHCl3) and subsequently visualized
with a Typhoon phosphorimager. (A) Radio-TLC of macrolactone production versus increased ACPdock concentration. (B) Plot of relative macrolac-
tone production versus ACPdock concentration. Error bars represent the standard deviation of replicate assays.have demonstrated that the helical amino-terminal dock-
ing domain participates in a coiled-coil structure in the
dimeric module [28]. This structural feature provides
a docking site for the helical carboxy-terminal docking do-
main of the preceding module [28]. Thus, we reasoned
that disruption of the overall helical structures of either
docking domain through short amino acid truncations
would be sufficient to prevent the normal protein-protein950 Chemistry & Biology 14, 944–954, August 2007 ª2007 Elseinteraction with their partner module. When paired with a
wild-type partner module, or each other, PikAIII(DDock)
and PikAIV(DDock) failed to generate the expected 14
membered ring macrolactone product, suggesting that
theshortdocking-domain truncationsdisrupted thenormal
interaction that occurs between the two monomodules.
Interestingly, 10-dml productionwas observed in all cases;
however, steady-state kinetic analysis demonstrated thatvier Ltd All rights reserved
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10-Deoxymethynolide Synthesis by the Pik PKSthe synthesis of this 12 membered ring macrolactone by
either PikAIII(DDock) or PikAIV(DDock) is much less effi-
cient (ca. 30- to 50-fold based on kcat) than that observed
with the combination of wild-type PikAIII and PikAIV (Table
1). One possible explanation for this observation is that
the ACP domains are not sufficiently phosphopantetheiny-
lated during protein expression, resulting in an overestima-
tion of the amount of active enzyme in the reaction
mixtures. However, rigorous analysis of the apo to holo
conversion of the ACP domains of both PikAIII(DDock)
and PikAIV(DDock) by FT-MS confirmed that the ACP
domains of the truncated modules were comparably mod-
ified relative to those of wild-type modules (Supplemental
Data). As such, it is reasonable to conclude from this data
that production of 10-dml by the pikromycin PKS system
requires PikAIII and PikAIV to be engaged in the docking-
domain protein-protein interaction.
Further evidence for the importance of the PikAIII-
PikAIV interaction in mediating macrolactone formation
was gained from competition experiments that utilized
the discrete C-terminal docking domain of PikAIII (ACP-
dock) to disrupt the normal PikAIII-PikAIV protein interac-
tion. Given the intrinsic specificity of C-terminal docking
domains for their N-terminal docking-domain partners
[22, 27, 28], we reasoned that the recombinant ACPdock
should compete with PikAIII for binding to PikAIV, thereby
resulting in an observed decrease in macrolactone pro-
duction. As expected, titration of ACPdock into reaction
mixtures containing wild-type PikAIII and PikAIV gave
a dose-dependent decrease in the generation of 10-dml
and narbonolide (Figure 5), suggesting that ACPdock is
indeed capable of precluding PikAIII and PikAIV from par-
ticipating in the normal protein-protein interaction. Impor-
tantly, a similar effect was not observed upon titration of
the reaction mixtures with a control peptide, the C-
terminal docking domain of DEBS2 (DEBS2 ACPdock),
under similar conditions. This indicates that the observed
competition is due to a specific interaction between
ACPdock and PikAIV. Consistent with the experiments
involving PikAIII(DDock) and PikAIV(DDock), these results
further emphasize the key role for docking domains in
the maintenance of the PikAIII-PikAIV protein-protein in-
teraction for macrolactone formation by the pikromycin
PKS.
Both PikAIII(DDock) and PikAIV(DDock) were capable of
supporting 10-dml synthesis, although at a much reduced
efficiency, when paired with each other or their wild-type
partner monomodule. Given this, it was compelling to
speculate that a direct interaction between the ACP5 do-
main of PikAIII and the terminal TE domain of PikAIV could
occur in a nonspecific manner to give low, nonphysiolog-
ical levels of 12 membered ring product formation. The
excised pikromycin TE domain demonstrated the ability
to cleave and cyclize the hexaketide intermediate from ei-
ther PikAIII or PikAIII(DDock). Furthermore, the calculated
kcat values are comparable to those determined from the
PikAIII-PikAIV(DDock) or PikAIII(DDock)-PikAIV pairings.
For comparison, 10-dml production by the combination
of PikAIII and the excised recombinant TE domainChemistry & Biology 14, 9appears to be less efficient compared to an engineered
PikAIII-TE fusion protein [18].
Taken together, the data reported here aremost consis-
tent with a model for 10-dml biosynthesis that involves TE
mediated lactonization of the PikAIII bound hexaketide in-
termediate within the context of the PikAIII-PikAIV protein-
protein interaction (Figure 6). This in vitro model assumes
that, upon interaction with PikAIII, PikAIV can adopt a con-
formation that places the terminal TE domain proximal to
the ACP5 domain of PikAIII. Although the dynamics of
PKS modules remain poorly understood, recent structural
information from both modular PKS systems [29–31] and
the related fatty acid synthase [32] suggest that individual
modules require inherent flexibility to enable ACP interac-
tion with all necessary catalytic domains. Accordingly, we
propose that when docked to PikAIII, PikAIV can adopt
a conformation that enables the terminal TE to interact
with the ACP of the preceding module.
Assuming a PikAIV conformational change is responsi-
ble for 10-dml biosynthesis, it is interesting to consider
what factors might influence this reorientation. The data
presented here highlight the importance of the docking-
domain interaction between PikAIII and PikAIV for
macrolactone production. However, it is likely that this
interaction alone is not sufficient to catalyze the PikAIV
reorientation, as it is also critical for the intermodular
substrate channeling that is necessary for narbonolide
production. One possible explanation is that an unloaded
ACP6 domain might signal a PikAIV conformational
change upon docking with PikAIII. That is, if the activity
of the AT domain within PikAIV is not sufficient to maintain
a steady supply of the acylated ACP6 domain, PikAIV may
convert to the proposed alternative conformation that
facilitates 10-dml production. Consistent with this possi-
bility, Wu et al. observed that the kcat value for PikAIV cat-
alyzed macrolactonization of the pikromycin synthetic
hexaketide intermediate was approximately 2-fold higher
in the absence of methylmalonyl-CoA [33].
Although further work is required to fully establish the
mechanistic details that are responsible for 10-dml pro-
duction by the pikromycin PKS, the in vitro studies re-
ported within provide strong evidence that the docking-
domain-mediated protein-protein interaction between
PikAIII and PikAIV is required for efficient generation of
the 12 membered ring macrolactone. However, we do
recognize that these data remain inconsistent with results
obtained from previous in vivo experiments. For example,
current and past in vitro data [18] do not support the initial
proposal that a truncated PikAIV is necessary for catalyz-
ing 10-dml formation [13]. It is possible that in vivo, the
PikAIV protein product suffers N-terminal truncations via
several likely mechanisms (e.g., alternative start site or
proteolysis) that may be dependent on growth medium.
As such, it cannot be ruled out that an N-terminally trun-
cated PikAIV is able to assume an effective alternative
interaction with PikAIII that can result in production of
10-dml in vivo. Likewise, previous in vivo experiments
suggested the importance of the KS, AT, and ACP domain
of PikAIV for 12 membered ring macrolactone production44–954, August 2007 ª2007 Elsevier Ltd All rights reserved 951
Chemistry & Biology
10-Deoxymethynolide Synthesis by the Pik PKSFigure 6. Proposed Model of 10-Deoxy-
methynolide Formation by the Pikromyin
Polyketide Synthase
Based on the current in vitro data, the efficient
production of 10-deoxymethynolide by the pik-
romycin PKS system requires that PikAIII and
PikAIV be engaged in their docking-domain-
mediated protein-protein interaction. A pre-
sumed conformational flexibility of PikAIV
enables the thioesterase domain to directly off-
load the hexaketide intermediate from PikAIII
to generate the 12 membered macrolactone
product.[15], although the in vitro studies reported herein oppose
this proposal.
While the results obtained in the current in vitro studies
are consistent with a role of docking-domain molecular
recognition in product formation, the complexity of the in
vivo system likely contributed to the previous observa-
tions. For example, the role of additional orthogonal fac-
tors (regulators, proteases, translational start sites) may
promote differential accumulation of macrolactone prod-
ucts in vivo. Consideration of these earlier investigations
requires a cautious interpretation of any refined in vitro
model as a potential oversimplification of events that oper-
ate to specify in vivo production of 10-dml. Nonetheless,
the results presented here strongly support a working
in vitro model for the mechanism of 10-dml synthesis by
the pikromycin PKS system whereby PikAIV serves as
a structural scaffold that presents the terminal TE domain
to the ACP5 domain of PikAIII (Figure 6). In this respect,
both in vivo [13] and in vitro models are coincident;
however, a complete understanding of the intricate mech-
anistic details require significant additional information,
such as insights into the macromolecular structure of
both PikAIII and PikAIV, as well as their inherent protein
dynamics.
SIGNIFICANCE
Polyketide natural products continue to be a rich
source of important biological activities, and efforts
that focus on understanding and manipulating the en-
zymes responsible for polyketide biosynthesis con-
tinue to hold tremendous promise for the discovery
anddevelopmentofnewmacrolide antibiotics. Theun-
precedented ability of the pikromycin PKS to generate
both 12 and 14 membered ring macrolactones makes
this system an important model system for under-
standing mechanistic details that can be leveraged
for the creation of novel polyketide compounds. While
it is well established that the interpolypeptide transfer
of polyketide intermediates within PKS systems is
facilitated by specific terminal docking-domain-medi-
ated interactions, the fate of the hexaketide intermedi-952 Chemistry & Biology 14, 944–954, August 2007 ª2007 Elsate produced by PikAIII remained unclear. The results
presented in this report clearly demonstrate that the
docking-domain interaction between PikAIII and
PikAIV that facilitates extension to the heptaketide in-
termediate for narbonolide production is also required
for efficient macrolactonization of the hexaketide into
10-dml. To date, this in vitro analysis represents the
most comprehensive, molecular study on the ability
of thepikromycinPKS toefficiently synthesizemultiple
macrolactone ring products.
EXPERIMENTAL PROCEDURES
Materials
Unless otherwise specified, all chemical reagents were purchased
from Sigma. DNA oligonucleotides were ordered from Integrated
DNA Technologies (Coralville, IA). Molecular cloning methods used
Pfu Turbo DNA polymerase from Invitrogen (Carlsbad, CA), New En-
gland Biolabs (Ipswich, MA) restriction enzymes, and T4 DNA polymer-
ase from Novagen (Madison, WI). LB Broth was from EM Sciences
(Gibbstown, NJ). Ni-NTA resin was purchased fromQIAGEN (Valencia,
CA), and PD-10 desalting and His-trap columns were from GE Health-
care (Piscataway, NJ). The synthesis of the pentaketide NAC thioester
has previously been described [18]. 2-[14C]-methylmalonyl-CoA
(55 mCi/mmol) was purchased from American Radiolabeled Chemi-
cals, Inc. (St. Louis, MO) and Tris [2-carboxyethyl phosphine] (TCEP)
was from Hampton Research (Aliso Viejo, CA). Silica TLC plates
were from EM Merck.
Construction of Mutant Pikromycin Monomodules
Site-directed mutants of PikAIV were generated by using QuikChange
site-directed mutagenesis (Stratagene) following the vendor’s proto-
cols. PikAIII(DDock) was generated via PCR amplification from the fol-
lowing primers: 50-gaggaggagcatatggcgaacaacgaagac-30 and 50-ga
gaagctttcacgacgcctccggctc-30. Following purification, the resulting
4.7 kb amplicon was digested with NdeI and HindIII and subsequently
ligated into a similarly digested wild-type pikAIII encoding plasmid
(pMPA405) to afford pPikAIII(DDock). Similarly, PikAIV(DDock) was
generated via PCR amplification with the following primer pair, 50-gag
gaggagcatatgtctctcaaggagaacgaa-30 and 50-gaggaggaggaattcgggt
gagctgtc-30, to give an approximate 1.5 kb amplicon encoding the de-
sired N-terminal truncation. Following double digestion with NdeI and
EcoRI, the PCR product was ligated into similarly digested wild-type
pikAIV encoding plasmid (pBB188) to afford pPikAIV(DDock).evier Ltd All rights reserved
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The expression of PikAIII, PikAIV, and the pikromycin thioesterase do-
main has previously been reported [20, 21, 23, 24]. The expression of
each mutant pikromycin module (point mutants of individual domains
and docking-domain truncations) was accomplished in BL21(DE3)
E. coli that contain a plasmid for the expression of the Bacillus subtilis
phosphopantetheinyl transferase (Sfp) [17]. Coexpression of the phos-
phopantetheinyl transferase was performed to ensure the efficient
posttranslational modification of ACP domains. In all cases, the previ-
ously reported expression conditions were followed [23].
Each polyhistidine-tagged module was subsequently purified by
nickel metal affinity chromatography. Cells from overexpression cul-
tures (typically 1 l) were harvested by centrifugation (5,000 3 g,
12 min, 4C) and resuspended in approximately 10–15 ml lysis buffer
(50mMNaH2PO4 [pH 8.0], 1mMDTT, 300mMNaCl, 10mM imidazole,
10% glycerol). After disruption by sonication (5 3 10 s with 50 s inter-
vening between pulses), the cellular debris was pelleted by centrifuga-
tion (40,000 g, 30min, 4C). The cell-free lysate was sterile filtered with
a 0.45 mm syringe filter after which Ni-NTA resin (1 ml) was directly
added to the filtered lysate and allowed to incubate for at least
30 min at 4C with shaking. Following transfer to a column, the Ni-
NTA resin was washed with additional lysis buffer (five column vol-
umes), followed by five column volumes of wash buffer (50 mM
NaH2PO4 [pH 8.0], 1 mM DTT, 300 mM NaCl, 30 mM imidazole, 10%
glycerol). The polyhistidine-tagged modules were eluted from the Ni-
NTA resin with five column volumes of elution buffer (50 mM NaH2PO4
[pH 8.0], 1 mM DTT, 300 mM NaCl, 300 mM imidazole, 10% glycerol)
and fractionated into 0.5ml fractions. Protein containing fractionswere
pooled and exchanged into storage buffer (100mMNaH2PO4 [pH 7.2],
1 mM DTT, 1 mM EDTA, 20% glycerol) by using PD-10 desalting col-
umns. Protein purity was confirmed to be greater than 95% by SDS-
PAGE. Purified proteins were flash frozen in liquid nitrogen and stored
at 80C. Final protein concentrations were determined by the Brad-
ford method with BSA standards.
In Vitro Activity Assay
The activity of the mutant pikromycin monomodules was assessed by
monitoring the incorporation of 2-[14C]-methylmalonyl-CoA into the re-
sulting 10-deoxymethynolide and narbonolide macrolactone products
by using the previously described radio-TLC assay [18]. Reactions
were performed in 400 mM NaH2PO4 buffer (pH 7.2) containing
5 mMNaCl, 1 mM TCEP, 1 mMNADPH, 20% glycerol, and 5%DMSO
in a final volume of 50 ml. In all cases, the enzyme concentrations were
held constant at 1 mM each. For steady-state kinetic determinations,
the concentration of the pentaketide NAC thioester substrate ranged
from 0.05–1 mM. In all cases, enzymes were equilibrated in buffer
with the pentaketide NAC thioester substrate for 5 min at 30C, after
which the reaction was initiated with the addition of 2-[14C]-methyl-
malonyl-CoA to a final, saturating concentration of 0.8 mM (diluted
for a specific activity ca. 1.0 mCi/mmol). Reactions were maintained
at 30C for 75 min, after which they were quenched by vortexing
with ethyl acetate (350 ml). The products were extracted once more
with ethyl acetate (250 ml). Both ethyl acetate fractions were pooled
and subsequently evaporated with a nitrogen stream. The resultant
oil was resuspended in dichloromethane (30 ml) and the entire suspen-
sion mixture was spotted onto silica gel TLC plates (20 3 20 cm with
2.5 cm concentration zone). Macrolactone products were resolved
by using a 5% methanol:chloroform solvent system. The TLC plate
was exposed to a phosphorimager screen for at least 24 hr, and the
radiolabeled products were subsequently visualized with a Typhoon
phosphorimager (Molecular Dynamics). For kinetic assays, macrolac-
tone product formation was quantified with the ImageQuant software
package (Molecular Dynamics) from a standard curve that was gener-
ated with 2-[14C]-methylmalonyl-CoA. Apparent kinetic parameters
were calculated from a nonlinear fit of the initial velocity data to the
Michaelis-Menten equation with the KaleidaGraph data analysis soft-
ware package (Synergy software). All kinetic parameters are calcu-
lated from at least three replicate determinations of initial velocityChemistry & Biology 14, 9data. The standard deviation from each point was calculated and is
represented graphically by the error bars in the data plots. The errors
for the fitted parameters are standard errors of the fits.
Docking-Domain Competition Experiments
The C-terminal docking domain (ACPdock) that extends from ACP5 of
PikAIII was amplified from pMPA405 and cloned into pMCSG7 by us-
ing ligation-independent cloning to generate pDHS9560 [34, 35]. The
PikAIII ACPdock insert was generated via PCR amplification from
the following primers: 50-tacttccaatccaatgccctccacgaggcgtacctcgc
ac-30 and 50-ttatccacttccaatgctaggtgttacgggggccgagagc-30. Simi-
larly, the C-terminal docking domain adjacent to ACP4 of DEBS2
from the erythromycin PKS was cloned into pMCSG7 to produce
pDHS9695 with the following primers: 50-tacttccaatccaatgcctccgcgg
ccagtccggcggtg and 50-ttatccacttccaatgctactacaggtcctctccccc-30.
Docking domains were overexpressed in BL21(DE3) E. coli and puri-
fied by nickel metal affinity chromatography, followed by preparative
gel filtration chromatography. Briefly, cells from 1 l overexpression cul-
tures were harvested by centrifugation (3,5003 g, 15min, 4C) and re-
suspended in 40 ml lysis buffer (20 mM HEPES [pH 7.5], 300 mM
NaCl, 20 mM imidazole, 1 mMMgCl2) containing 1 g CelLytic Express.
After disruption by sonication (53 30 s with 30 s between pulses), clar-
ified cell lysate was generated via centrifugation (20,000 3 g, 30 min,
4C). Following filtration of the supernatant with a 0.45 mm filter, the ly-
sate was loaded onto a 5ml His-trapHP column. After washing the col-
umn with 2.5 column volumes of lysis buffer, the polyhistidine-tagged
docking domains were eluted with an imidazole gradient (20–400 mM).
Proteins were concentrated with Amicon Ultra devices (5,000 dalton
MWCO). Docking domains were further purified by gel fitration on
a Pharmacia Superdex S75 column in HEPES buffered saline (HBS:
20 mM HEPES [pH 7.5], 150 mM NaCl). Following concentration,
docking domains were stored at80C in HBS. Protein concentration
was determined by comparison to a BSA standard by using the BCA
protein assay method. For competition experiments, ACPdock
(0–500 mM) was titrated into reaction mixtures (50 ml) containing
1 mM each PikAIII and PikAIV, 0.4 mM pentaketide NAC thioester,
and 0.8 mM 2-[14C]-methylmalonyl-CoA (diluted for a specific activity
of 1.0 mCi/mMol) in 400 mM NaH2PO4 buffer (pH 7.2) supplemented
with 5 mM NaCl, 1 mM TCEP, 1 mM NADPH, 20% glycerol, and 5%
DMSO. Following 20 min incubation at 30C, the reactions were
quenched and assessed for macrolactone production as described
above.
Supplemental Data
Supplemental Data include SDS-PAGE analysis of the PikAIII(DDock)
and PikAIV(DDock), the Michaelis-Menten plot of 10-dml production
by wild-type PikAIII and PikAIV, and the FT-ICR mass spectrometry
analysis of phosphopantetheinylated ACP domains and are available
at http://www.chembiol.com/cgi/content/full/14/8/944/DC1/.
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